FUNDED PROJECTS:
CANCER

All funded projects

cartell MaratóIn the 2012 Marató, which dealt with cancer, 318 projects were presented and these were assessed by 257 scientists specialising in these diseases, according to their quality, methodology and relevance. This assessment was managed by the Agency for Health Quality and Assessment of Catalonia, of the Catalan Ministry of Health.
In accordance with the proposal of the scientific Advisory Committee of the Fundació La Marató de 3Cat, the Board agreed to distribute € 11,336.546 to the following 42 research projects of excellence:

Characterisation of the oncogenic molecular mechanisms of transcription factor SOX11 in aggressive mantle cell lymphomas

  • Dra. Virginia Amador Espinosa
    IDIBAPS Institut d'Investigació Biomèdica August Pi i Sunyer
Fund: 195.026,25 €

Identification and characterisation of metastasis-initiating cells in human squamous cell carcinoma: a basic, clinical approach

  • Dr. Salvador Aznar Benitah
    Institut de Recerca Biomèdica de Barcelona
Fund: 199.930 €

Gene expression profile of the glioblastomas, including LINCRNA (large intergenic non-coding RNA), in a homogeneous population: correlation with the immunophenotype, radiology, results

  • Dra. Carmen Balañá Quintero
    Institut Català d'Oncologia Badalona
  • Dra. Núria de la Iglesia Zaragoza
    IDIBAPS Institut d'Investigació Biomèdica August Pi i Sunyer
  • Dr. Francesc Alameda Quitllet
    Hospital del Mar
Fund: 393.380,05 €

Analysis of whole genomes and exomes of primary lymphomas of mantle cells

  • Dra. Sílvia M. Beà Bobet
    IDIBAPS Institut d'Investigació Biomèdica August Pi i Sunyer
Fund: 199.995 €

Molecular characterisation of non-small-cell lung carcinoma (NSCLC) with mutations to the KRAS gene: clinical implications of the new biomarkers

  • Dra. Beatriz Bellosillo Paricio
    IMIM-Institut de Recerca Hospital del Mar
  • Dr. Imane Chaib Oukadour
    Institut Català d'Oncologia Badalona
Fund: 300.000 €

Population evaluation of the impact of compliance with the Clinical Practice Guideline Programme (GCP) and of adherence to oral hormone therapy on survival and recurrence in breast cancer patients

  • Dr. Josep Maria Borràs Andrés
    Institut Català d'Oncologia IDIBELL
Fund: 182.120,23 €

Memory T stem cells transduced with a chimeric anti-CD30 receptor for treatment of Hodgkin lymphoma

  • Dr. Javier Briones Meijide
    Hospital de la Santa Creu i Sant Pau
Fund: 192.462,5 €

New technologies as non-invasive tools for the prognosis/diagnosis of stomach cancer

  • Dr. Xavier Calvet Calvo
    Corporació Sanitària Parc Taulí
  • Dr. David Miñana i Galbis
    Facultat de Farmàcia UB
  • Dr. Guillermo Quintás Soriano
    Acondicionamiento Tarrasense-LEITAT
Fund: 399.892,5 €

Antitumoral activity of analogues of the a-galactosyl/ceramide iNKT activators: towards immunotherapeutic reagents

  • Dr. Ángel Raúl Castaño García
    Institut Biotecnologia i Biomedicina UAB
Fund: 190.250 €

New cyclins: filling a gap in the biology of cancer

  • Dr. Josep Clotet Erra
    Facultat Medicina i Ciències de la Salut UIC
Fund: 81.875 €

Modelling pancreatic ductal adenocarcinoma by means of reprogramming

  • Dra. Ina Berniakovich
    CMRB Centre Medicina Regenerativa de Barcelona
Fund: 199.633,75 €

Role of Phf19 in controlling tumour development, proliferation and progression

  • Dr. Luciano di Croce
    Centre de Regulació Genòmica
Fund: 197.500 €

IKKa activated as a new biomarker and possible therapeutic target for colorectal cancer

  • Dr. Lluís Espinosa Blay
    IMIM Institut Hospital del Mar d'Investigacions Mèdiques
Fund: 200.000 €

Predicting advanced colonic neoplasia by an immunochemical faecal occult blood test, the patient's clinical symptoms and a scoring system: a prospective multicentre study

  • Dr. Fernando Fernández Bañares
    Hospital Universitari Mútua de Terrassa
Fund: 180.762,5 €

Role of RNA-binding proteins in the progression of melanoma: searching for new diagnostic markers and therapeutic targets

  • Dra. Fátima Gebauer Hernández
    Centre de Regulació Genòmica
  • Dra. M. Soledad Soengas González
    Centro Nacional de Investigaciones Oncológicas CNIO
Fund: 300.000 €

The RANK pathway as a new therapeutic strategy in HER2+ and HER2+ resistant breast cancer

  • Dra. Eva González Suárez
    IDIBELL Institut d'Investigació Biomèdica de Bellvitge
  • Dra. Teresa Puig Miquel
    Facultat de Medicina. Universitat de Girona
Fund: 290.511,25 €

Antisense transcription and epigenetic regulation in cancer

  • Dra. Sònia Guil Domènech
    IDIBELL Institut d'Investigació Biomèdica de Bellvitge
Fund: 156.579,87 €

Molecular analysis of capicua, a new tumour suppressor implicated in RTK signalling and transcriptional repression

  • Dr. Gerardo Jiménez Cañero
    Institut Biologia Molecular de Barcelona CSIC- ICREA
  • Dr. Mariano Barbacid Montalbán
    Centro Nacional de Investigaciones Oncológicas CNIO
Fund: 279.375 €

The cancer genome interpreter

  • Dra. Núria López Bigas
    Institut de Recerca Biomèdica de Barcelona
Fund: 195.000 €

Soluble scavenger lymphocyte receptors as new immunomodulating agents in cancer

  • Dr. Francisco Lozano Soto
    IDIBAPS Institut d'Investigació Biomèdica August Pi i Sunyer
  • Dra. Gloria González Aseguinolaza
    Centro para la Investigación Médica Aplicada Pamplona
  • Dra. Yvonne Saenger
    Mount Sinai School of Medicine NY
Fund: 350.000 €

Genotoxic nanoparticles aimed at colorectal cancer stem cells

  • Dr. Ramon Mangues Bafalluy
    Institut Recerca Hospital Sta. Creu i St. Pau
  • Dr. Antonio Villaverde Corrales
    Institut Biotecnologia i Biomedicina UAB
  • Dr. Ramon Eritja Casadellà
    Institut Química Avançada de Catalunya CSIC
Fund: 399.975 €

Analysis of whole DNA (hydroxy)methylome and of the transcriptome in multiple myeloma

  • Dr. José I. Martín Subero
    Facultat de Medicina UB
  • Dr. Felipe Prósper Cardoso
    Clínica Universitaria de Navarra
  • Dra. Puri Fortes Alonso
    Centro de Investigación Médica Aplicada
Fund: 359.079,87 €

Genomic study for the personalised management of endometrial cancer (diagnosis, prognosis and treatment)

  • Dr. Xavier Matias-Guiu Guia
    IRBLL Institut Recerca Biomèdica de Lleida
  • Dr. Antonio Gil Moreno
    VHIR Institut de Recerca Hospital Universitari Vall d'Hebron
  • Dra. Gema Moreno Bueno
    Fundación MD Anderson International España
  • Dr. José Palacios Calvo
    Hospital Universitario Ramón y Cajal
Fund: 397.895 €

IdentificacióStructure-based identification of new inhibitors of the xCT glutamate transporter for the treatment of gliomas

  • Dr. Manuel Palacín Prieto
    Institut Recerca Biomèdica de Barcelona
  • Dr. Juan Fernández Recio
    Barcelona Supercomputing Center
Fund: 299.062,5 €

Finding the readers of oxidised histone H3 and new oxidases of histone H3

  • Dra. Sandra Peiró Sales
    IMIM Institut Hospital del Mar d'Investigacions Mèdiques
Fund: 198.918,2 €

Proliferation and survival pathways in chemotherapy-resistant cancer stem cells

  • Dra. Mileidys Pérez Alea
    VHIR Institut de Recerca Hospital Universitari Vall d'Hebron
  • Dr. Ruggero De Maria
    Instituti Fisioterapici Ospedalieri
Fund: 300.000 €

Bifunctional compounds against cannabinoids and of chemokine receptors to inhibit cellular proliferation and interactions in the tumoral microenvironment

  • Dra. Patricia Pérez Galán
    IDIBAPS Institut d'Investigació Biomèdica August Pi i Sunyer
  • Dr. Peter McCormick
    School of Pharmacy. University of East Anglia Norwich
  • Dr. Joan Bosch Cartes
    Facultat de Farmàcia UB
Fund: 399.631,25 €

Anion transporters as efficient pH dysregulation molecules: a preclinical and translational study

  • Dr. Ricardo Pérez Tomás
    Facultat de Medicina UB
  • Dr. Modesto Orozco López
    Institut Recerca Biomèdica de Barcelona
  • Dr. Roberto Quesada Pato
    Facultad de Ciencias UBU
Fund: 398.772,5 €

Signalling through the single domain of Src kinases in colorectal cancer

  • Dr. Miquel Pons Vallès
    Facultat de Química UB
  • Dr. Serge Roche
    Centre National de Recherche Scientifique CNRS UMR5237 Montpeller
Fund: 298.908,75 €

Blood concentrations of organochlorate compounds, lifestyle and risk of pancreatic cancer in the EPIC cohort

  • Dr. Miquel Porta Serra
    IMIM Institut Hospital del Mar d'Investigacions Mèdiques
Fund: 199.915,1 €

The ZEB proteins in tumoral progression. Role of ZEB1 and ZEB2 in oncogenic transformation, transition benign-malignant and proliferation and survival of the cancerous cell

  • Dr. Antonio Postigo
    IDIBAPS Institut d'Investigació Biomèdica August Pi i Sunye
Fund: 200.000 €

Implementation of personalised medicine based on genetic susceptibility and molecular signatures in the tumour in the cutaneous melanoma: identification of new targets for the treatment of the melanoma

  • Dra. Susanna Puig Sardà
    IDIBAPS Institut d'Investigació Biomèdica August Pi i Sunyer
  • Dra. Rosa Maria Martí Laborda
    Hospital Universitari Arnau de Vilanova
  • Dra. Àngels Fabra Fres
    IDIBELL Institut d'Investigació Biomèdica de Bellvitge
  • Dr. Santiago Nonell Marrugat
    Institut Químic de Sarrià URL
  • Dr. Joaquín Dopazo Blázquez
    Centro de Investigación Príncipe Felipe València
Fund: 324.750 €

Prospective multicentre strategy to improve the cure of acute high-risk leukaemias promoting a platform for timely allogenic therapy in patients without an identical HLA dono

  • Dr. Sergio Luis Querol Giner
    Bang de Sang i Teixits
  • Dr. Ramón Gimeno Martínez
    IMIM Institut Hospital del Mar d'Investigacions Mèdiques
Fund: 297.538,25 €

Stromal rigidity in tumour progression

  • Dr. Pere Roca-Cusachs Soulere
    Institut Bioenginyeria de Catalunya IBEC
  • Dr. Miguel Á. del Pozo Barriuso
    Centro Nacional de Investigaciones Cardiovasculares Carlos III
Fund: 299.657,5 €

Study of the relationship between inflammation and colon cancer through the p38 MAP kinase signalling pathway

  • Dr. Àngel Rodríguez Nebreda
    Institut Recerca Biomèdica de Barcelona IRB
  • Dra. Ana Cuenda Méndez
    Centro Nacional de Biotecnologia CSIC
Fund: 300.000 €

Confocal endomicroscopic diagnosis of the pulmonary nodule in lung cancer screening programmes

  • Dr. Antoni Rosell Gratacós
    Hospital Universitari de Bellvitge
Fund: 199.989,375 €

Role of the Spa scavenger protein in the interaction between macrophages, hepatic stellate cells and hepatocytes in liver cancer

  • Dra. Maria Rosa Sarrias Fornés
    Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol
Fund: 191.250 €

Lipotoxicity, hepatic steatosis and hepatocarcinoma: function of the armc10/armcx family of mitochondrial proteins

  • Dr. Eduardo Soriano García
    Universitat de Barcelona UB
  • Dr. Francesc Villarroya Gombau
    CIBER Fisiopatología de la Obesidad y Nutrición
  • Dra. Beatriz Mínguez Rosique
    Hospital Universitari Vall d'Hebron
Fund: 398.687,5 €

Determining the suppressor activity of SirT6 tumours: the role of epigenetic factors Suv39h1 and G9a

  • Dr. Alejandro Vaquero García
    IDIBELL Institut d'Investigació Biomèdica de Bellvitge
Fund: 198.750 €

Personalised nanomedicine for triple negative breast cancer stem cells

  • Dra. Esther Vázquez Gómez
    Institut Biotecnologia i Biomedicina UAB
  • Dra. Ibane Abasolo Olaortua
    CIBBIM Programa de Nanomedicina HVd'H
  • Dra. Míriam Royo Expósito
    Parc Científic de Barcelona
Fund: 393.095,9 €

Role of the ORMDL proteins (a new family of regulating proteins of sphingolipid biosynthesis) in the antitumoral effect of cannabinoids

  • Dr. Rubén Vicente García
    Universitat Pompeu Fabra UPF
  • Dr. Guillermo Velasco Díez
    Instituto Investigaciones Sanitarias HC San Carlos - Facultad de Biología U. Complutense
Fund: 297.250 €

Exploring lethal synthetic interactions between PARP and response to DNA damage in treatments against cancer

  • Dr. José Yélamos López
    IMIM Institut Hospital del Mar d'Investigacions Mèdiques
  • Dr. Óscar Fernández-Capetillo Ruiz
    Centro Nacional de Investigaciones Oncológicas CNIO
Fund: 299.125 €
Anar al contingut